Vital health parameters of the 2 volunteers, who are administered the Oxford Covid-19 vaccine candidate at a medical college in Pune as a part of the clinical test phase II clinical trial , are normal, a senior official from the medical facility said on Thursday.
Two men, aged 32 and 48, got the primary shot of the ‘Covishield’ vaccine, being manufactured by Pune-based Serum Institute of India (SII), at Bharti Vidyapeeth’s Medical College and Hospital on Wednesday. The dose are going to be repeated after one month, a politician said.
“Since yesterday, our medical team is in-tuned with the 2 volunteers and both are fine. they are doing not have any pain, fever, injection-side reaction or systemic illness post-vaccination,” the medical college and hospital’s deputy medical director Dr Jitendra Oswal said.
After the vaccine was administered on Wednesday, both the volunteers were observed for half-hour and later allowed to travel home, he said.
With 75,760 new cases, India’s Covid count crosses 33-lakh mark
After 75,760 new cases were recorded within the last 24 hours, India’s coronavirus tally crossed 33-lakh mark on Thursday. With 1,023 new deaths, the cumulative toll has reached 60,472 deaths.The Covid-19 case tally within the country climbed to 33,10,235 including 7,25,991 active cases, 25,23,772 cured/discharged/migrated.
“They are given all the required emergency numbers (to contact just in case of need) and our medical team is additionally conducting follow-ups with them,” he added.
The vaccine dose are going to be repeated on both the volunteers after one month, the hospital’s medical director Dr Sanjay Lalwani said on Wednesday.
He said altogether , 25 candidates are going to be given the vaccine within the next seven days.
Dr Sonali Palkar, in-charge of the medical college’s research cell, said four to 5 persons were screened on Wednesday and a choice to administer the vaccine to them as a part of the clinical test is subject to their Covid-19 and antibody test reports.
SII, the world’s largest vaccine maker has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University together with British-Swedish pharma company AstraZeneca.